Structure of the Elastin-Contractile Units in the Thoracic Aorta and How Genes That Cause Thoracic Aortic Aneurysms and Dissections Disrupt This Structure

Canadian Journal of Cardiology

Volumn 32, Issue 1, 2016, Pages 26-34

  Karimi, Ashkan ^a   Milewicz, Dianna M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTIN; MYOSIN HEAVY CHAIN; PHOSPHOTRANSFERASE; STRUCTURAL PROTEIN; DNA;

ALPHA ACTIN 2 GENE; AORTA DISSECTION; BLOOD VESSEL; ELASTIN CONTRACTILE UNIT; ELASTIN GENE; EMILIN 1 GENE; FIBRILLIN 1 GENE; FIBULIN 4 GENE; FILAMIN A GENE; GENE; GENE DISRUPTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MECHANOTRANSDUCTION; MFAP5 GENE; MUSCLE TISSUE; MYOSIN LIGHT CHAIN KINASE GENE; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; SMC SPECIFIC ISOFORM OF MYOSIN HEAVY CHAIN GENE; SMOOTH MUSCLE CONTRACTION; THORACIC AORTA; THORACIC AORTA ANEURYSM; THORACIC AORTIC DISSECTION; TYPE I CGMP DEPENDENT PROTEIN KINASE GENE; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; DISSECTING ANEURYSM; GENETICS; GENOTYPE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANEURYSM, DISSECTING; ANIMALS; AORTA, THORACIC; AORTIC ANEURYSM, THORACIC; DNA; ELASTIN; GENOTYPE; HUMANS; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; VASOCONSTRICTION;

EID: 84951813416     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.11.004     Document Type: Review

References (74)

1. Osler W. Aneurysm of the abdominal aorta. Lancet 1905, 2:1089-1096.
2. Pape L.A., Tsai T.T., Isselbacher E.M., et al. Aortic diameter > or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007, 116:1120-1127.
3. Milewicz D.M., Regalado E.S. Use of genetics for personalized management of heritable thoracic aortic disease: how do we get there?. J Thorac Cardiovasc Surg 2015, 149:S3-5.
4. Hiratzka L.F., Bakris G.L., Beckman J.A., et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J Am Coll Cardiol 2010, 55:e27-e129.
5. Babes V., Mironescu T. Ueber dissezierende Arteriitis und Aneurysma dissecans. Beitr path Anat 1910, 48:221. [About dissecting arteritis and dissecting aneurysm], [in German].
6. Erdheim J. Medionecrosis aortae idiopathica (cystica) [Cystic medial necrosis]. Archiv für pathologische Anatomie und Physiologie und für klinische Medizin [Archive for Pathological Anatomy and Physiology and for Clinical Medicine] 1929, 273:454-479. [in German].
7. Tang P.C., Coady M.A., Lovoulos C., et al. Hyperplastic cellular remodeling of the media in ascending thoracic aortic aneurysms. Circulation 2005, 112:1098-1105.
8. He R., Guo D.-C., Estrera A.L., et al. Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections. J Thorac Cardiovasc Surg 2006, 131:671-678.
9. Davis E.C. Smooth muscle cell to elastic lamina connections in developing mouse aorta. Role in aortic medial organization. Lab Invest 1993, 68:89-99.
10. Ismail E.-H., Magdi H.Y. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol 2009, 6:771-786.
11. Milewicz D.M., Guo D.C., Tran-Fadulu V., et al. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet 2008, 9:283-302.
12. Humphrey J.D., Milewicz D.M., Tellides G., Schwartz M.A. Cell biology. Dysfunctional mechanosensing in aneurysms. Science 2014, 344:477-479.
13. Humphrey J.D., Schwartz M.A., Tellides G., Milewicz D.M. Role of mechanotransduction in vascular biology: focus on thoracic aortic aneurysms and dissections. Circ Res 2015, 116:1448-1461.
14. Small J.V., Gimona M. The cytoskeleton of the vertebrate smooth muscle cell. Acta Physiol Scand 1998, 164:341-348.
15. George J.C., Alexander P.N., Kevin Kit P. The role of mechanotransduction on vascular smooth muscle myocytes cytoskeleton and contractile function. Anat Rec 2014, 297:1758-1769.
16. Kim B.S., Nikolovski J., Bonadio J., Mooney D.J. Cyclic mechanical strain regulates the development of engineered smooth muscle tissue. Nat Biotechnol 1999, 17:979-983.
17. Li X.D., Saito J., Ikebe R., Mabuchi K., Ikebe M. The interaction between the regulatory light chain domains on two heads is critical for regulation of smooth muscle myosin. Biochemistry 2000, 39:2254-2260.
18. Kamm K.E., Stull J.T. Dedicated myosin light chain kinases with diverse cellular functions. J Biol Chem 2001, 276:4527-4530.
19. Li D.Y., Brooke B., Davis E.C., et al. Elastin is an essential determinant of arterial morphogenesis. Nature 1998, 393:276-280.
20. Li D.Y., Faury G., Taylor D.G., et al. Novel arterial pathology in mice and humans hemizygous for elastin. J Clin Invest 1998, 102:1783-1787.
21. Wagenseil J.E., Mecham R.P. Vascular extracellular matrix and arterial mechanics. Physiol Rev 2009, 89:957-989.
22. Khau Van Kien P., Mathieu F., Zhu L., et al. Mapping of familial thoracic aortic aneurysm/dissection with patent ductus arteriosus to 16p12.2-p13.13. Circulation 2005, 112:200-206.
23. Loeys B.L., Schwarze U., Holm T., et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006, 355:788-798.
24. Nicod P., Bloor C., Godfrey M., et al. Familial aortic dissecting aneurysm. J Am Coll Cardiol 1989, 13:811-819.
25. Biddinger A., Rocklin M., Coselli J., Milewicz D.M. Familial thoracic aortic dilatations and dissections: a case control study. J Vasc Surg 1997, 25:506-511.
26. Milewicz D.M., Chen H., Park E.S., et al. Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. Am J Cardiol 1998, 82:474-479.
27. Marfan A. Un cas de déformation congénitale des quatre membres, plus prononcée aux extrémités, caractérisée par lállongement des os avec un certain degré dámincissement. Bull Mem Soc Med Hop (Paris) 1896, 13:220-226. [A Case of congenital deformation of four extremities characterized by elongation of the bones with uncertain degree of thinning]., [in French].
28. Keane M.G., Pyeritz R.E. Medical management of Marfan syndrome. Circulation 2008, 117:2802-2813.
29. Sakai L.Y., Keene D.R., Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol 1986, 103:2499-2509.
30. Kainulainen K., Pulkkinen L., Savolainen A., Kaitila I., Peltonen L. Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med 1990, 323:935-939.
31. Maslen C.L., Corson G.M., Maddox B.K., Glanville R.W., Sakai L.Y. Partial sequence of a candidate gene for the Marfan syndrome. Nature 1991, 352:334-337.
32. Magenis R.E., Maslen C.L., Smith L., Allen L., Sakai L.Y. Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics 1991, 11:346-351.
33. Collod-Beroud G., Le Bourdelles S., Ades L., et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 2003, 22:199-208.
34. Faivre L., Collod-Beroud G., Loeys B.L., et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 2007, 81:454-466.
35. Milewicz D.M. Identification of defects in the fibrillin gene and protein in individuals with the Marfan syndrome and related disorders. Tex Heart Inst J 1994, 21:22-29.
36. Jensen S.A., Aspinall G., Handford P.A. C-terminal propeptide is required for fibrillin-1 secretion and blocks premature assembly through linkage to domains cbEGF41-43. Proc Natl Acad Sci U S A 2014, 111:10155-10160.
37. Raghunath M., Putnam E.A., Ritty T., et al. Carboxy-terminal conversion of profibrillin to fibrillin at a basic site by PACE/furin-like activity required for incorporation in the matrix. J Cell Sci 1999, 112:1093-1100.
38. Milewicz D.M., Grossfield J., Cao S.N., et al. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest 1995, 95:2373-2378.
39. Hollister D.W., Godfrey M., Sakai L.Y., Pyeritz R.E. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med 1990, 323:152-159.
40. Milewicz D.M., Pyeritz R.E., Crawford E.S., Byers P.H. Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. J Clin Invest 1992, 89:79-86.
41. Dietz H.C., Saraiva J.M., Pyeritz R.E., Cutting G.R., Francomano C.A. Clustering of fibrillin (FBN1) missense mutations in Marfan syndrome patients at cysteine residues in EGF-like domains. Hum Mutat 1992, 1:366-374.
42. Whiteman P., Hutchinson S., Handford P.A. Fibrillin-1 misfolding and disease. Antiox Redox Signal 2006, 8:338-346.
43. Suk J.Y., Jensen S., McGettrick A., et al. Structural consequences of cysteine substitutions C1977Y and C1977R in calcium-binding epidermal growth factor-like domain 30 of human fibrillin-1. J Biol Chem 2004, 279:51258-51265.
44. Jones J.A., Spinale F.G., Ikonomidis J.S. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res 2009, 46:119-137.
45. Ramirez F., Pereira L. The fibrillins. Int J Biochem Cell Biol 1999, 31:255-259.
46. Barbier M., Gross M.S., Aubart M., et al. MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. Am J Hum Genet 2014, 95:736-743.
47. Capuano A, Bucciotti F, Farwell KD, et al. Diagnostic exome sequencing identifies a novel gene, EMILIN1, associated with autosomal dominant hereditary connective tissue disease [e-pub ahead of print]. Hum Mutat, accessed November 3, 2015. doi:10.1002/humu.22920.
48. Szabo Z., Crepeau M.W., Mitchell A.L., et al. Aortic aneurysmal disease and cutis laxa caused by defects in the elastin gene. J Med Genet 2006, 43:255-258.
49. Hucthagowder V., Sausgruber N., Kim K.H., et al. Fibulin-4: a novel gene for an autosomal recessive cutis laxa syndrome. Am J Hum Genet 2006, 78:1075-1080.
50. Renard M., Holm T., Veith R., et al. Altered TGFbeta signaling and cardiovascular manifestations in patients with autosomal recessive cutis laxa type I caused by fibulin-4 deficiency. Eur J Hum Genet 2010, 18:895-901.
51. Morisaki H., Akutsu K., Ogino H., et al. Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD). Hum Mutat 2009, 30:1406-1411.
52. Disabella E., Grasso M., Gambarin F.I., et al. Risk of dissection in thoracic aneurysms associated with mutations of smooth muscle alpha-actin 2 (ACTA2). Heart 2011, 97:321-326.
53. Guo D.C., Pannu H., Tran-Fadulu V., et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007, 39:1488-1493.
54. Lu H., Fagnant P.M., Bookwalter C.S., Joel P., Trybus K.M. Vascular disease-causing mutation R258C in ACTA2 disrupts actin dynamics and interaction with myosin. Proc Natl Acad Sci U S A 2015, 112:E4168-E4177.
55. Regalado E.S., Guo D.C., Prakash S., et al. Aortic disease presentation and outcome associated with ACTA2 mutations. Circ Cardiovasc Genet 2015, 8:457-464.
56. Guo D.C., Papke C.L., Tran-Fadulu V., et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 2009, 84:617-627.
57. Dianna M.M., John R.Ø., Leena M.A., et al. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A 2010 Oct, 152A(10):2437-2443.
58. Pannu H., Tran-Fadulu V., Papke C.L., et al. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet 2007, 16:2453-2462.
59. Zhu L., Vranckx R., Khau Van Kien P., et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 2006, 38:343-349.
60. Harakalova M., van der Smagt J., de Kovel C.G., et al. Incomplete segregation of MYH11 variants with thoracic aortic aneurysms and dissections and patent ductus arteriosus. Eur J Hum Genet 2013, 21:487-493.
61. Wang L., Guo D.C., Cao J., et al. Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet 2010, 87:701-707. [erratum in 2011;88:516].
62. Guo D.C., Regalado E., Casteel D.E., et al. Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J Hum Genet 2013, 93:398-404.
63. Yue J., Huhn S., Shen Z. Complex roles of filamin-A mediated cytoskeleton network in cancer progression. Cell Biosci 2013, 3:7.
64. Pilop C., Aregger F., Gorman R.C., et al. Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. Circulation 2009, 120:983-991.
65. Sheen V.L., Jansen A., Chen M.H., et al. Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology 2005, 64:254-262.
66. Sheen V.L., Walsh C.A. Periventricular heterotopia: new insights into Ehlers-Danlos syndrome. Clin Med Res 2005, 3:229-233.
67. LeMaire S.A., Russell L. Epidemiology of thoracic aortic dissection. Nat Rev Cardiol 2011, 8:103-113.
68. Hatzaras I., Tranquilli M., Coady M., et al. Weight lifting and aortic dissection: more evidence for a connection. Cardiology 2007, 107:103-106.
69. Hsue P.Y., Salinas C.L., Bolger A.F., Benowitz N.L., Waters D.D. Acute aortic dissection related to crack cocaine. Circulation 2002, 105:1592-1595.
70. Eagle K.A., Isselbacher E.M., DeSanctis R.W. Cocaine-related aortic dissection in perspective. Circulation 2002, 105:1529-1530. International Registry for Aortic Dissection (IRAD) Investigators.
71. Inamoto S., Kwartler C.S., Lafont A.L., et al. TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. Cardiovasc Res 2010, 88:520-529.
72. Boileau C., Guo D.C., Hanna N., et al. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet 2012, 44:916-921.
73. Lindsay M.E., Schepers D., Bolar N.A., et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet 2012, 44:922-927.
74. Huang J., Yamashiro Y., Papke C.L., et al. Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. Sci Transl Med 2013, 5:183ra158. 1-11.